Pathway Diagram

flowchart TD
    APP["APP Gene<br/>(Amyloid Precursor Protein)"]
    
    APP -->|"encodes"| APP_protein["APP Protein"]
    APP_protein -->|"processed by"| secretases["gamma-secretase and<br/>beta-secretase"]
    secretases -->|"produces"| amyloid_beta["Amyloid Beta<br/>('Abeta peptides[')"]
    
    amyloid_beta -->|"aggregates into"| plaques["Amyloid Plaques"]
    plaques -->|"triggers"| neuroinflammation["Neuroinflammation"]
    plaques -->|"causes"| synaptic_loss["Synaptic<br/>Dysfunction"]
    
    neuroinflammation -->|"leads to"| neurodegeneration["Neurodegeneration"]
    synaptic_loss -->|"contributes to"| neurodegeneration
    
    APP -->|"causes"| EOAD["Early-Onset<br/>Alzheimer's Disease"]
    APP -->|"causes"| familial_AD["Familial<br/>Alzheimer's Disease"]
    
    neurodegeneration -->|"manifests as"| alzheimer["Alzheimer's<br/>Disease"]
    neurodegeneration -->|"associated with"| parkinson["Parkinson's<br/>Disease"]
    neurodegeneration -->|"linked to"| ALS["Amyotrophic<br/>Lateral Sclerosis"]
    
    APP -->|"biomarker for"| aging["Aging Process"]
    APP -->|"biomarker for"| senescence["Cellular<br/>Senescence"]
    
    APP -->|"therapeutic target"| therapy["Therapeutic<br/>Interventions"]
    therapy -->|"aims to reduce"| amyloid_beta
    
    style APP fill:#006494
    style therapy fill:#1b5e20
    style plaques fill:#ef5350
    style neuroinflammation fill:#ef5350
    style neurodegeneration fill:#ef5350
    style secretases fill:#4a1a6b
    style alzheimer fill:#5d4400
    style EOAD fill:#5d4400
    style familial_AD fill:#5d4400

APP — Amyloid Precursor Protein

Overview

APP (Amyloid Precursor Protein) is a gene located on chromosome 21q21.3 that encodes a type I transmembrane protein critical for neuronal health and central to the pathogenesis of Alzheimer’s disease (AD) and related neurodegenerative disorders^{1The amyloid precursor protein gene is on chromosome 211987 · Science · DOI 10.1126/science.2880399Open reference}. The APP protein is sequentially cleaved by alpha-, beta-, and gamma-secretases through two mutually exclusive proteolytic pathways, generating various peptide fragments including amyloid-beta (Aβ) peptides when processed via the amyloidogenic pathway^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}.

The amyloid cascade hypothesis, first proposed in 1992, posits that accumulation of Aβ peptides in the brain triggers a cascade of pathological events including neurofibrillary tangle formation, synaptic loss, and neuronal death^{3Alzheimer's disease: the amyloid cascade hypothesis1992 · Science · DOI 10.1126/science.1072994Open reference}. While this hypothesis has undergone significant refinement over decades of research, APP and its proteolytic processing remain central to AD therapeutic strategies.

APP is one of the most intensively studied genes in neuroscience due to its pivotal role in neurodegeneration. Triplication of APP on chromosome 21 in Down syndrome leads to early-onset AD pathology, providing human genetic evidence for APP’s causal role in amyloid deposition^{4Aging in Down syndrome and the development of Alzheimer's disease neuropathology2016 · J Alzheimers Dis · PMID 26485706Open reference}.

Molecular Biology of APP

Gene Structure and Isoforms

The APP gene spans approximately 350 kb and consists of 18 exons. Alternative splicing generates multiple isoforms:

• APP770: Full-length isoform containing the KPI domain and exon 15, widely expressed

• APP751: Includes KPI domain, expressed in most tissues

• APP695: Neuron-specific isoform lacking KPI domains, predominant in brain

The APP protein contains several functional domains:

Extracellular domain:

• N-terminal signal peptide

• Copper-binding domain (CuBD)

• KPI domain (Kunitz-type protease inhibitor)

• Amyloid-beta (Aβ) region (residues 681-770)

Transmembrane domain:

• Single pass transmembrane helix

• Site of gamma-secretase cleavage

Cytoplasmic domain:

• Intracellular signaling domain

• Tyrosine-based sorting motifs

• C-terminal interaction sites

APP Processing Pathways

APP undergoes proteolytic processing through two mutually exclusive pathways^{5Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE1999 · Science · DOI 10.1126/science.286.5440.735Open reference6The gamma-secretase complex: membrane-embedded proteolytic assembly2009 · Cell · PMID 19250922Open reference}:

Amyloidogenic Pathway (Aβ-Generating)

This pathway generates Aβ peptides through sequential cleavage:

1. Beta-secretase (BACE1) cleavage: BACE1 (Beta-site APP-cleaving enzyme 1) cleaves APP at the N-terminus of the Aβ domain (Met-681), generating the membrane-bound C-terminal fragment C99 and soluble APPβ (sAPPβ)^{5Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE1999 · Science · DOI 10.1126/science.286.5440.735Open reference}

2. Gamma-secretase cleavage: The presenilin-containing gamma-secretase complex (comprising PSEN1 or PSEN2, PEN-2, APH-1, and NCT) cleaves C99 within the transmembrane domain at multiple sites, releasing Aβ peptides of varying lengths^{6The gamma-secretase complex: membrane-embedded proteolytic assembly2009 · Cell · PMID 19250922Open reference}

The Aβ40 peptide (40 amino acids) is the predominant species generated (~90%), while Aβ42 has greater aggregation propensity and is the primary constituent of amyloid plaques. Longer species (Aβ43, Aβ45) are also produced but less abundant.

Non-Amyloidogenic Pathway (Aβ-Preventing)

This pathway precludes Aβ formation:

1. Alpha-secretase cleavage: ADAM10 (A Disintegrin and Metalloproteinase domain 10) cleaves APP within the Aβ domain (between Lys-16 and Leu-17 of Aβ), generating sAPPα and the C-terminal fragment C83^{7Constitutive and regulated alpha-secretase cleavage of Alzheimer's amyloid precursor protein by a disintegrin metalloproteinase1999 · Proc Natl Acad Sci USA · DOI 10.1073/pnas.96.7.3922Open reference}

2. Gamma-secretase cleavage: Subsequent gamma-secretase cleavage of C83 releases the non-amyloidogenic p3 fragment

This pathway is considered neuroprotective and is the target of some therapeutic strategies aimed at shifting APP processing away from amyloidogenic toward non-amyloidogenic processing.

Normal Physiological Functions

Beyond its central role in AD pathogenesis, APP serves important normal physiological functions^{8Physiological functions of APP and its role in neurodegeneration2014 · Neurodegener Dis · PMID 25643397Open reference}:

Synaptic Function and Plasticity

APP is highly expressed in synaptic compartments and participates in synaptic formation, maintenance, and plasticity:

• Regulates synaptic structure and function

• Involved in long-term potentiation (LTP)

• Mediates excitatory synaptic transmission

• Supports dendritic spine morphology

• Functions as a synaptic adhesion molecule

Neuronal Development

During brain development, APP regulates:

• Neuronal migration

• Axonal growth and guidance

• Synaptogenesis

• Myelin formation

• Neuronal survival through neurotrophic signaling

Metal Ion Binding and Homeostasis

APP binds copper (Cu+) and zinc (Zn2+) ions through its N-terminal copper-binding domain:

• Plays roles in metal ion homeostasis

• Antioxidant responses through copper sequestration

• Cellular redox regulation

Cell Adhesion and Signaling

APP functions as a synaptic adhesion molecule, participating in:

• Neuronal survival signaling through interaction with Frizzled receptors

• Synaptic contact formation

• Membrane protein interactions

• Regulation of cell proliferation

Peripheral Tissue Functions

In non-neural tissues, APP is expressed at lower levels and functions in:

• Platelet activation and wound healing

• Muscle development

• Iron export (in conjunction with ferroportin)

APP in Alzheimer’s Disease

Amyloid Cascade Hypothesis

The amyloid cascade hypothesis remains foundational to AD pathogenesis research^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}0^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}1:

1. Genetic mutations causing increased Aβ production (APP, PSEN1, PSEN2) lead to familial AD

2. Aβ oligomerization and plaque formation ensue

3. Synaptic dysfunction and neuronal loss follow

4. Tau pathology develops as a downstream consequence

While the hypothesis has been refined—acknowledging that soluble Aβ oligomers rather than plaques may be the toxic species—the central role of APP/Aβ in AD remains well-established.

APP Mutations in Familial AD

Over 50 pathogenic APP mutations cause autosomal dominant Alzheimer’s disease (ADAD)^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}2:

These mutations provide direct genetic evidence linking APP to AD pathogenesis and have been instrumental in developing therapeutic strategies.

Down Syndrome and APP

Individuals with Down syndrome (trisomy 21) develop early-onset AD pathology by age 40-50 due to APP gene dosage effect^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}3:

• APP triplication leads to approximately 1.5-fold increase in Aβ production

• Aβ deposition begins in the third decade of life

• Nearly all individuals with DS develop AD-type pathology by age 60

• Provides human genetic model for APP-induced neurodegeneration

APP in Other Neurodegenerative Diseases

Cerebral Amyloid Angiopathy (CAA)

APP mutations cause hereditary cerebral amyloid angiopathy characterized by^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}4:

• Aβ deposition in cerebral blood vessel walls (predominantly Aβ40)

• Recurrent hemorrhagic strokes

• Cognitive decline

• Dutch type (E693Q) and Iowa type (D694N) mutations

Parkinson’s Disease

Emerging evidence links APP to Parkinson’s disease^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}5:

• Increased APP expression in PD substantia nigra

• Aβ colocalization with Lewy bodies in some cases

• APP promoter variants associated with PD risk

• Interactions between APP processing and alpha-synuclein pathology

Traumatic Brain Injury

Chronic traumatic encephalopathy (CTE) shows^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}6:

• Increased APP expression following head trauma

• Aβ accumulation in athletes with repetitive brain injury

• May represent a second hit that accelerates neurodegeneration

Other Disorders

• Huntington’s Disease: Altered APP processing may contribute to neurodegeneration

• Amyotrophic Lateral Sclerosis: APP expression changes in motor neurons

• Frontotemporal Dementia: Some cases show Aβ comorbidity

Therapeutic Targeting

Secretase Modulators

Beta-secretase (BACE1) inhibitors: Multiple BACE1 inhibitors reached clinical trials but were discontinued due to adverse effects^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}7:

• Verubecestat: Discontinued due to cognitive worsening

• Lanabecestat: Halted for safety concerns

• Umibecestat: Stopped for cognitive decline

The failure of BACE1 inhibitors highlights the importance of APP’s normal physiological functions and suggests that complete inhibition may be deleterious.

Alpha-secretase activators: ADAM10 activation represents a therapeutic approach to shift APP processing toward the non-amyloidogenic pathway, though clinical development remains challenging.

Anti-Aβ Immunotherapy

Active and passive immunization approaches targeting Aβ have shown clinical success^{2Mutation of the amyloid precursor protein in familial Alzheimer's disease1992 · Science · DOI 10.1126/science.2111584Open reference}8:

Monoclonal antibodies:

• Lecanemab: FDA-approved, reduces brain amyloid

• Donanemab: FDA-approved, removes plaques

• Aducanumab: FDA-approved, controversial efficacy

Mechanisms:

• Promote amyloid plaque clearance

• Reduce soluble Aβ oligomers

• May modulate microglial activation

Adverse effects:

• ARIA (Amyloid-Related Imaging Abnormalities)

• Amyloid-related edema (ARIA-E)

• Microhemorrhages (ARIA-H)

APP-Targeting Approaches

Emerging strategies include:

• Small molecules modulating APP trafficking

• Gene therapy approaches

• RNA interference targeting APP expression

• Vaccine development targeting multiple Aβ species

Disease-Modifying Strategies

Given the central role of APP/Aβ, several approaches aim to intervene at different points:

APP Family and Splice Variants

The APP gene family includes:

• APP: The canonical gene discussed here

• APLP1 (Amyloid Precursor-Like Protein 1)

• APLP2 (Amyloid Precursor-Like Protein 2)

APP undergoes alternative splicing, generating multiple isoforms:

• APP695: Neuron-specific, lacking KPI domain

• APP751: Including KPI domain

• APP770: Full-length with both KPI and exon 15

APLP family members share functional domains but lack the Aβ sequence and cannot generate amyloid peptides.

Brain Expression Pattern

APP exhibits region-specific expression throughout the brain:

Expression data from the Allen Human Brain Atlas confirms highest expression in cortical and hippocampal regions vulnerable to AD pathology.

Single-Cell Expression

APP is expressed in multiple neuronal and glial cell types:

• Glutamatergic neurons (highest)

• GABAergic neurons

• Oligodendrocyte precursors

• Astrocytes Microglia (lower levels)

Interaction Network

APP interacts with numerous proteins relevant to neurodegeneration:

Biomarker Potential

APP Metabolites as Biomarkers

APP processing products serve as diagnostic biomarkers:

CSF biomarkers:

• sAPPα and sAPPβ: Markers of alpha- and beta-secretase activity

• Aβ42/Aβ40 ratio: Diagnostic for AD

• Total tau and phospho-tau: Neurodegeneration markers

Imaging biomarkers:

• Amyloid PET: Visualizes plaque burden

• Florbetapir, Florbetaben: FDA-approved tracers

Blood-based biomarkers:

• Aβ42/Aβ40 ratio: Emerging blood test

• p-tau181, p-tau217: Phosphorylated tau fragments

Research Tools and Resources

Mouse Models

Cell Lines

• SH-SY5Y: Neuroblastoma, expresses APP

• HEK293: Frequently used for APP processing studies

• Primary neurons: Cortical and hippocampal cultures

• iPSC-derived neurons: Patient-specific models

Clinical Considerations

Diagnosis

APP-related biomarkers inform AD diagnosis:

• Decreased CSF Aβ42 correlates with plaque burden

• Increased CSF sAPPβ indicates BACE1 activity

• PET amyloid positivity precedes clinical symptoms

Treatment Response

Therapeutic efficacy is monitored through:

• Amyloid PET reduction

• CSF Aβ42 changes

• Clinical outcome measures

• ARIA monitoring for immunotherapy

Prevention

Given APP’s central role, prevention strategies include:

• Lifestyle modifications reducing vascular risk

• Early amyloid detection

• Potential prophylactic immunotherapy (in development)

Genetic Epidemiology

APP Mutations and Population Genetics

The APP gene shows significant variation across populations:

Pathogenic mutations: Over 50 pathogenic variants have been identified, predominantly in families with early-onset autosomal dominant AD. These mutations cluster around the secretase cleavage sites and Aβ coding region.

Risk variants: Genome-wide association studies have identified common variants near APP that influence AD risk:

• SNPs in the APP promoter region affect expression levels

• Variants in regulatory elements may modify risk

• Population-specific effects require further study

APP copy number variation:

• APP duplication causes autosomal dominant early-onset AD (ADAD)

• Down syndrome (trisomy 21) provides natural model of APP overdose

• Triplication alone is sufficient for Aβ deposition

Founder Effects

Several APP mutations show founder effects:

• Swedish family: KM670/671NL mutation in large Swedish kindred

• Volga German families: Multiple PSEN1 and APP mutations in families of German ancestry

• British families: APP V717I mutation in British families with AD

Cellular Mechanisms

APP Trafficking and Processing

The subcellular localization of APP determines its processing pathway:

Secretory pathway: APP is synthesized in the endoplasmic reticulum and travels through the Golgi apparatus to the plasma membrane. Surface APP can be internalized and routed to endosomes where beta-secretase activity is highest.

Endosomal sorting: BACE1 localizes primarily to endosomes, making this compartment the primary site of amyloidogenic processing. The intracellular domain of APP contains sorting motifs that direct this trafficking.

Synaptic APP: At synapses, APP accumulates in pre-synaptic vesicles and is released activity-dependently, potentially serving as a signaling molecule.

Aβ Aggregation

The aggregation of Aβ into oligomers and plaques represents a critical pathological process:

Nucleation: Aβ monomers aggregate into oligomers, which serve as nuclei for further aggregation.

Oligomer toxicity: Soluble Aβ oligomers (rather than plaques) are considered the most toxic species, disrupting synaptic function and causing neuronal dysfunction.

Plaque formation: As aggregation proceeds, insoluble fibrils form and deposit as plaques. Plaques may represent a protective mechanism, sequestering toxic oligomers.

APP and Calcium Homeostasis

APP processing affects cellular calcium signaling:

• Gamma-secretase cleavage releases the APP intracellular domain, which can influence calcium channel expression

• Aβ can form calcium-permeable pores in membranes

• Calcium dysregulation contributes to synaptic dysfunction

APP and Mitochondrial Function

Aβ accumulates in mitochondria and contributes to:

• Mitochondrial dysfunction

• Oxidative stress

• Energy deficits

• Apoptosis induction

Neuroimmunology

APP and Microglial Activation

The relationship between APP and microglia is bidirectional:

Microglial receptors for Aβ:

• RAGE (Receptor for Advanced Glycation Endproducts) binds Aβ and triggers inflammation

• TLR4 (Toll-like Receptor 4) recognizes Aβ and activates innate immunity

• CD36 contributes to Aβ-induced inflammatory responses

Microglial clearance:

• Microglia can phagocytose Aβ

• TREM2 on microglia promotes Aβ clearance

• Impaired clearance contributes to plaque accumulation

Inflammatory cytokines influence APP processing:

• TNF-α increases BACE1 expression

• IL-1β modulates APP transcription

• Chronic inflammation may accelerate pathology

APP in Neuroinflammation

Aβ triggers inflammatory responses:

• Cytokine release (IL-1β, IL-6, TNF-α)

• Reactive oxygen species generation

• Complement activation

• Chronic neuroinflammation

Therapeutic Challenges

Lessons from Clinical Trials

The history of APP-targeted therapy provides crucial insights:

BACE1 inhibitor failures: The discontinuation of multiple BACE1 inhibitors due to cognitive worsening taught important lessons:

• BACE1 has essential physiological functions

• Complete inhibition is detrimental

• Timing of intervention may be critical

• Biomarker-driven patient selection needed

Immunotherapy successes and challenges:

• Amyloid removal is achievable

• Clinical benefit is modest

• ARIA is a significant adverse effect

• Early intervention may be more effective

Combination Therapy

Future approaches may combine:

• Anti-amyloid and anti-tau therapies

• Immunotherapy with small molecules

• Targeting neuroinflammation

• Symptomatic treatments

Personalized Medicine

Approaches to personalized APP-targeted therapy:

• Genetic testing for APP mutations

• Biomarker stratification

• Age at intervention optimization

• Polygenic risk scores

See Also

• Amyloid-beta Protein

• Alzheimer’s Disease

• Cerebral Amyloid Angiopathy

• BACE1

• Gamma-secretase

• Tau Protein

• Down Syndrome

External Links

• NCBI Gene

• Ensembl

• OMIM

• UniProt

• Allen Human Brain Atlas - APP

• Alzheimer’s Disease Neuroimaging Initiative

Related Hypotheses

From the SciDEX Exchange — scored by multi-agent debate

• Context-Dependent CRISPR Activation in Specific Neuronal Subtypes — 0.62 · Target: Cell-type-specific essential genes

• Trinucleotide Repeat Sequestration via CRISPR-Guided RNA Targeting — 0.59 · Target: HTT, DMPK, repeat-containing transcripts

• Epigenetic Memory Reprogramming for Alzheimer's Disease — 0.55 · Target: BDNF, CREB1, synaptic plasticity genes

• Cholesterol-CRISPR Convergence Therapy for Neurodegeneration — 0.55 · Target: HMGCR, LDLR, APOE regulatory regions

• Metabolic Reprogramming via Coordinated Multi-Gene CRISPR Circuits — 0.53 · Target: PGC1A, SIRT1, FOXO3, mitochondrial biogenesis genes

• Programmable Neuronal Circuit Repair via Epigenetic CRISPR — 0.45 · Target: NURR1, PITX3, neuronal identity transcription factors

• Multi-Modal CRISPR Platform for Simultaneous Editing and Monitoring — 0.42 · Target: Disease-causing mutations with integrated reporters

Related Analyses:

• CRISPR-based therapeutic approaches for neurodegenerative diseases 🔄

Pathway Diagram

The following diagram shows the key molecular relationships involving APP — Amyloid Precursor Protein discovered through SciDEX knowledge graph analysis:

graph TD
    ad_genetic_risk_loci_APP["ad_genetic_risk_loci:APP"] -->|"data in"| APP["APP"]
    benchmark_ot_ad_answer_key_APP["benchmark_ot_ad_answer_key:APP"] -->|"data in"| APP["APP"]
    AMYLOID["AMYLOID"] -.->|"inhibits"| APP["APP"]
    NEURODEGENERATION["NEURODEGENERATION"] -->|"associated with"| APP["APP"]
    ALZHEIMER["ALZHEIMER"] -->|"activates"| APP["APP"]
    AMYLOID["AMYLOID"] -->|"activates"| APP["APP"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"associated with"| APP["APP"]
    ALZHEIMER_S_DISEASE["ALZHEIMER'S DISEASE"] -->|"therapeutic target"| APP["APP"]
    INFLAMMATION["INFLAMMATION"] -->|"activates"| APP["APP"]
    APOPTOSIS["APOPTOSIS"] -->|"activates"| APP["APP"]
    APOE["APOE"] -->|"associated with"| APP["APP"]
    APOPTOSIS["APOPTOSIS"] -->|"associated with"| APP["APP"]
    APP_PS1["APP/PS1"] -.->|"inhibits"| APP["APP"]
    AMYLOID["AMYLOID"] -->|"associated with"| APP["APP"]
    APP_PS1["APP/PS1"] -->|"activates"| APP["APP"]
    style ad_genetic_risk_loci_APP fill:#4fc3f7,stroke:#333,color:#000
    style APP fill:#ce93d8,stroke:#333,color:#000
    style benchmark_ot_ad_answer_key_APP fill:#4fc3f7,stroke:#333,color:#000
    style AMYLOID fill:#ce93d8,stroke:#333,color:#000
    style NEURODEGENERATION fill:#ce93d8,stroke:#333,color:#000
    style ALZHEIMER fill:#ce93d8,stroke:#333,color:#000
    style ALZHEIMER_S_DISEASE fill:#ce93d8,stroke:#333,color:#000
    style INFLAMMATION fill:#ce93d8,stroke:#333,color:#000
    style APOPTOSIS fill:#ce93d8,stroke:#333,color:#000
    style APOE fill:#ce93d8,stroke:#333,color:#000
    style APP_PS1 fill:#ce93d8,stroke:#333,color:#000

Associated Diseases

• Als — associated with
  View disease page

• ALS — associated with
  View disease page

• Alzheimer — associated with
  View disease page

• Alzheimer disease — causes
  View disease page

• Alzheimer’s disease — associated with
  View disease page

• Alzheimer’s Disease — causes
  View disease page

• Alzheimer’S Disease — biomarker for
  View disease page

• Amyotrophic Lateral Sclerosis — causes
  View disease page

• Autosomal Dominant Alzheimer’s Disease — causes
  View disease page

• dementia — associated with
  View disease page

• Dementia — associated with
  View disease page

• Familial Alzheimer’s Disease — associated with
  View disease page

• frontotemporal dementia — associated with
  View disease page

• Frontotemporal Dementia — causes
  View disease page

• Parkinson — associated with
  View disease page

• Parkinson’s disease — associated with
  View disease page

• PARKINSON’S DISEASE — associated with
  View disease page

• Parkinson’s Disease with Dementia — implicated in
  View disease page